'Flying Banana' traveling 125 mph fires laser into sky and catches aurora hunters off guard (video)
When you buy through links on our articles, Future and its syndication partners may earn a commission.
On two separate nights in May, a strange blue laser sliced through the skies over the Oxfordshire, England countryside, leaving skywatchers baffled. Astrophotographer and astronomy communicator Mary McIntyre captured the eerie spectacle on her remote aurora-hunting cameras — and what she saw didn't match anything she'd encountered before.
"The first time I spotted it [May 1], I thought at first it may have been a rare form of blue aurora but then realised it was moving too quickly," McIntyre told Space.com in an email. "It just didn't fit with any other aurora we've seen during the 30 or so displays we've captured."
Suspecting a spotlight from a nearby RAF base sometimes used for film sets, McIntyre considered that theory, then ruled it out due to the light's speed.
Maybe lights from a festival? McIntyre had seen those before, too, but not like this. "We've had lights from festivals before now, but again they looked nothing like this, plus this blue beam was in the sky in the early hours of the morning rather than evening."
It wasn't until McIntyre's husband shared the footage from May 1 that a friend in the astronomy community offered an explanation — a high-speed mapping train with a fruity nickname.
The culprit for the strange blue light show is a specialized train that records track condition information using lasers at speeds of up to 125 mph. It is officially known as the New Measurement Train (NMT), but its bright yellow paintwork has earned it the playful nickname "Flying Banana".
"I couldn't believe it when I spotted it on our cameras again in the early hours of 29th May!" McIntyre said.
"While it looks very cool, it's also a shame to have yet another thing that's polluting the night sky," McIntyre continued.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory
We came across a bullish thesis on Coherus BioSciences, Inc. (CHRS) on Steve Wagner's Substack. In this article, we will summarize the bulls' thesis on CHRS. Coherus BioSciences, Inc. (CHRS)'s share was trading at $0.77 as of 30th May. CHRS's trailing P/E was 1.77 according to Yahoo Finance. Scientist in a lab working on a research project, focusing on biotechnology and healthcare advancements. Coherus BioSciences (CHRS), long overlooked by Wall Street, is taking a bold step into innovative oncology by partnering with UK-based STORM Therapeutics to test a novel cancer treatment strategy. The collaboration brings together Coherus's immunotherapy toripalimab (LOQTORZI) and STORM's first-in-class RNA-modifying enzyme inhibitor STC-15 in a Phase 1b/2 clinical trial. This unexpected pairing represents a fresh approach to immuno-oncology, targeting cancer through dual mechanisms that could produce synergistic effects. Toripalimab, already approved in the U.S. for nasopharyngeal carcinoma and under review for broader indications, offers proven checkpoint inhibition, while STC-15 introduces a cutting-edge method of disrupting RNA methylation processes linked to tumor growth and immune evasion. If this combo demonstrates efficacy, it could represent a completely new class of cancer therapy and place Coherus at the forefront of next-generation immuno-oncology innovation. Importantly, this partnership shows strategic vision from CHRS's management as they seek to differentiate the company beyond biosimilars and move deeper into proprietary immunotherapy. With the trial still in early stages and little market attention so far, the risk/reward profile for investors is potentially skewed to the upside. Should the data prove positive, the impact could be significant for both companies, especially for CHRS as it repositions itself as a serious player in oncology innovation. This under-the-radar development deserves close monitoring, as it could catalyze a major reevaluation of Coherus's valuation and growth trajectory. Previously, we have covered CHRS in March 2025 wherein we summarized a by the same author. Coherus BioSciences (CHRS) posted a strong turnaround in 2024 with $267M in revenue and $28.5M net income, driven by Loqtorzi's growth and the planned $250M Udenyca divestiture. The company pivoted fully to oncology, trimmed costs, and advanced its pipeline, yet management expressed frustration over the stock's undervaluation, hinting at potential M&A. Since our last coverage, the stock is down 38% as of 30th May. We don't trust CHRS' management as the stock lost more than 95% of its value in recent years and is still losing a ton of money. The market agrees with us and thinks this stock is going to go bankrupt. We believe CHRS should stop wasting shareholder's money, sell valuable assets, and liquidate the company. We don't think that's a likely outcome. Coherus BioSciences, Inc. (CHRS) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 10 hedge fund portfolios held CHRS at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of CHRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Doctors try 'poo pills' to flush out dangerous superbugs
UK doctors are attempting to clear dangerous superbug infections using "poo pills" containing freeze-dried faeces. The stool samples come from healthy donors and are packed with good bacteria. Early data suggests superbugs can be flushed out of the dark murky depths of the bowel and replaced with a mix of healthy gut bacteria. It is a new approach to tackling infections that resist antibiotics, which are thought to kill a million people each year. The focus is on the bowels which are "the biggest reservoir of antibiotic resistance in humans" says Dr Blair Merrick, who has been testing the pills at Guys and St Thomas' hospitals. Drug-resistant superbugs can escape their intestinal home and cause trouble elsewhere in the body – such as urinary tract or bloodstream infections. "So there's a lot of interest in 'can you get rid of them from the gut?'," says Dr Merrick. The idea of poo-pills isn't as far-fetched as it might seem. Faecal transplants – also known as a trans-poo-tion - are already approved for treating severe diarrhoea caused by Clostridium difficile bacteria. But scientists noticed hints that faecal transplants for C. difficile also seemed to get rid of superbugs. Microbiome podcast: Manipulating Our Hidden Half New research has focused on patients who had an infection caused by drug-resistant bacteria in the past six months. They were given pills made from faeces which people had donated to a stool bank. Each stool sample is tested to ensure it does not contain any harmful bugs, undigested food is removed and then it is freeze dried into a powder. This is stored inside a pill that can pass through the stomach unscathed and reach the intestines where it dissolves to release its poopy powdery payload. The trial has taken place on 41 patients at Guy's and St Thomas' hospitals in London to lay the groundwork for a large-scale study. It showed patients were up for taking a poo pill and the donated bacteria were still being detected in the bowels at least a month later. Dr Merrick says there are "really promising signals" that poo pills could help tackle the rising scourge of superbugs and that donor bacteria could be going to microbial war with the superbugs as they compete over food and space on the lining of the gut and either rid the body of them completely or "reduce them down to a level that doesn't cause problems". The study also suggests the array of gut bacteria becomes more varied after the therapy. This is a sign of good health and "may well be promoting colonisation resistance" so it is harder for new infectious bugs to get in. "It's very exciting. There's a real shift from 20 years ago where all bacteria and viruses were assumed to do you harm; to now where we realise they are completely necessary to our overall health," says Dr Merrick. Earlier this week scientists showed the good bacteria our bodies meet – in the hours after we are born – seem to halve the risk of young children being admitted to hospital with lung infections. First bacteria we ever meet can keep us out of hospital More than half your body is not human Our body's own human cells are outnumbered by the bacteria, fungi and others that live inside us - known as the microbiome. This has led to research implicating the microbiome in everything from Crohn's disease to cancer to mental health. If poo pills are proven to work against superbugs in larger studies then the researchers think they could be used for both treatment and prevention in people at risk. Medical procedures that suppress the immune system - including cancer therapies and organ transplants - can make the body more vulnerable. "A lot of these individuals come to a lot of harm from drug resistant organisms," Dr Merrick. The UK's drugs regulator – the Medicines and Healthcare Products Agency – said there were more than 450 microbiome medicines currently in development. "Some of them will success, so I do think we will seem them coming through quite soon," said Dr Chrysi Sergaki, the head of microbiome research at the MHRA. "We could potentially, in the future, replace antibiotics with microbiome [therapies] - that's the big picture, so there's a lot of potential."
Yahoo
3 hours ago
- Yahoo
Doctors try 'poo pills' to flush out dangerous superbugs
UK doctors are attempting to clear dangerous superbug infections using "poo pills" containing freeze-dried faeces. The stool samples come from healthy donors and are packed with good bacteria. Early data suggests superbugs can be flushed out of the dark murky depths of the bowel and replaced with a mix of healthy gut bacteria. It is a new approach to tackling infections that resist antibiotics, which are thought to kill a million people each year. The focus is on the bowels which are "the biggest reservoir of antibiotic resistance in humans" says Dr Blair Merrick, who has been testing the pills at Guys and St Thomas' hospitals. Drug-resistant superbugs can escape their intestinal home and cause trouble elsewhere in the body – such as urinary tract or bloodstream infections. "So there's a lot of interest in 'can you get rid of them from the gut?'," says Dr Merrick. The idea of poo-pills isn't as far-fetched as it might seem. Faecal transplants – also known as a trans-poo-tion - are already approved for treating severe diarrhoea caused by Clostridium difficile bacteria. But scientists noticed hints that faecal transplants for C. difficile also seemed to get rid of superbugs. Microbiome podcast: Manipulating Our Hidden Half New research has focused on patients who had an infection caused by drug-resistant bacteria in the past six months. They were given pills made from faeces which people had donated to a stool bank. Each stool sample is tested to ensure it does not contain any harmful bugs, undigested food is removed and then it is freeze dried into a powder. This is stored inside a pill that can pass through the stomach unscathed and reach the intestines where it dissolves to release its poopy powdery payload. The trial has taken place on 41 patients at Guy's and St Thomas' hospitals in London to lay the groundwork for a large-scale study. It showed patients were up for taking a poo pill and the donated bacteria were still being detected in the bowels at least a month later. Dr Merrick says there are "really promising signals" that poo pills could help tackle the rising scourge of superbugs and that donor bacteria could be going to microbial war with the superbugs as they compete over food and space on the lining of the gut and either rid the body of them completely or "reduce them down to a level that doesn't cause problems". The study also suggests the array of gut bacteria becomes more varied after the therapy. This is a sign of good health and "may well be promoting colonisation resistance" so it is harder for new infectious bugs to get in. "It's very exciting. There's a real shift from 20 years ago where all bacteria and viruses were assumed to do you harm; to now where we realise they are completely necessary to our overall health," says Dr Merrick. Earlier this week scientists showed the good bacteria our bodies meet – in the hours after we are born – seem to halve the risk of young children being admitted to hospital with lung infections. First bacteria we ever meet can keep us out of hospital More than half your body is not human Our body's own human cells are outnumbered by the bacteria, fungi and others that live inside us - known as the microbiome. This has led to research implicating the microbiome in everything from Crohn's disease to cancer to mental health. If poo pills are proven to work against superbugs in larger studies then the researchers think they could be used for both treatment and prevention in people at risk. Medical procedures that suppress the immune system - including cancer therapies and organ transplants - can make the body more vulnerable. "A lot of these individuals come to a lot of harm from drug resistant organisms," Dr Merrick. The UK's drugs regulator – the Medicines and Healthcare Products Agency – said there were more than 450 microbiome medicines currently in development. "Some of them will success, so I do think we will seem them coming through quite soon," said Dr Chrysi Sergaki, the head of microbiome research at the MHRA. "We could potentially, in the future, replace antibiotics with microbiome [therapies] - that's the big picture, so there's a lot of potential."
